Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments
1 other identifier
observational
55
1 country
1
Brief Summary
The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 4, 2024
CompletedFirst Posted
Study publicly available on registry
June 7, 2024
CompletedStudy Start
First participant enrolled
November 25, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2026
December 4, 2025
November 1, 2025
1.6 years
June 4, 2024
November 27, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Responses to qualitative interview questions
Interview questions designed to gather insights into diagnosis, symptoms, current treatments, perspectives on treatment features and test for mock preferences tasks. The interview will take 15 minutes to complete.
Day 1
Patient sociodemographic
Day 1
Patient clinical characteristics
Day 1
Study Arms (2)
Patients with a diagnosis of resectable non-small cell lung cancer (NSCLC)
Physicians currently treating resectable non-small cell lung cancer (NSCLC) patients
Interventions
As prescribed by treating physician
Eligibility Criteria
Adults participants with a diagnosis of resectable NSCLC and physicians treating patients with resectable NSCLC residing in US, Germany or Japan.
You may qualify if:
- Patients
- Aged ≥18 years at the time of enrollment in the study
- Resident of the US, Germany, or Japan
- Able to read, speak, and understand English, German or Japanese
- Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)
- Physicians
- Resident of the US, Germany, or Japan
- Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology
- Treated at least three new patients with resectable NSCLC in the past year
You may not qualify if:
- Patients
- Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
- Being diagnosed with another malignancy alongside NSCLC
- Not willing to be audio-recorded during the interview
- Physicians
- Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
- Not willing to be audio-recorded during the interview
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Evidera
London, United Kingdom
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bristol-Myers Squibb
Bristol-Myers Squibb
Central Study Contacts
First line of the email MUST contain NCT # and Site #.
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 4, 2024
First Posted
June 7, 2024
Study Start
November 25, 2024
Primary Completion (Estimated)
June 30, 2026
Study Completion (Estimated)
June 30, 2026
Last Updated
December 4, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share